(MENAFN- Investor Brand Network)
- Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing
- Lexaria's patented DehydraTECH (TM) technology is undergoing human clinical trials this year to determine its effectiveness in making cannabidiol (“CBD”) effective as a means of reducing blood pressure for high blood pressure patients
- The initial results of the first human clinical study showed the DehydraTECH-CBD compound was well tolerated by patients without troubling side effects and that the compound outperformed generic CBD controls
- Just-released initial (partial) results regarding the compound's second human clinical trial show that a three-dose regimen was effective in reducing systolic pressure, mean arterial pressure and diastolic pressure as compared with a placebo when monitored for 24 hours
Technology innovator Lexaria Bioscience (NASDAQ: LEXX) is celebrating the initial (partial) results from its human clinical trial pitting its patented flagship platform DehydraTECH (TM), in combination with cannabidiol (“CBD”), against a placebo to measure how blood pressure patients respond to Lexaria's patented technology.
Lexaria's HYPER-H21-2 human clinical study follows on the heels of initial clinical testing that showed DehydraTECH-CBD produced a reduction in blood pressure in both male and female volunteers and…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company's newsroom at
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
303.498.7722 Office
CBDWire is part of the InvestorBrandNetwork .
MENAFN13092021000224011066ID1102791631
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.